Endometriosis Patients Undergoing Quinagolide Treatment

Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00625950

Enrollment

Registered

2008-02-29

Start date

2008-02-29

Completion date

2008-05-31

Last updated

2009-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis, Hyperprolactinemia

Keywords

Hyperprolactinemia, Endometriosis, laparoscopy, angiogenesis, VEGF

Brief summary

Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.

Interventions

PROCEDUREENDOMETRIAL BIOPSY

Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 37 Years

Healthy volunteers

Inclusion criteria

* Hyperprolactinemia * Unexplained infertility * Endometriosis

Design outcomes

Primary

Measure	Time frame
observation of three month treatment with Quinagolida in endometriosis patients	onset and three months after onset

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026